{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:07:50Z","timestamp":1759482470145},"reference-count":64,"publisher":"Media Sphere Publishing Group","issue":"8. Vyp. 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. nevrol. psikhiatr. im. S.S. Korsakova"],"published-print":{"date-parts":[[2015]]},"DOI":"10.17116\/jnevro20151158225-35","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T09:59:40Z","timestamp":1460627980000},"page":"25","source":"Crossref","is-referenced-by-count":10,"title":["A prospective, open, non-randomized study on the safety and efficacy of natalizumab (tisabri) in the Russian population of patients with relapsing-remitting multiple sclerosis"],"prefix":"10.17116","volume":"115","author":[{"given":"A. N.","family":"Boyko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. P.","family":"Evdoshenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. V.","family":"Vorob\u2019eva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Pukaite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro20151158225-35-1","doi-asserted-by":"crossref","unstructured":"Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502-1517.","DOI":"10.1016\/S0140-6736(08)61620-7"},{"key":"key-10.17116\/jnevro20151158225-35-2","doi-asserted-by":"crossref","unstructured":"Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122:1180-1188.","DOI":"10.1172\/JCI58649"},{"key":"key-10.17116\/jnevro20151158225-35-3","unstructured":"National Multiple Sclerosis Society. Relapse-remitting MS. 2014; Available at: http:\/\/www.nationalmssociety.org\/What-is-MS\/Types-of-MS\/Rel\u00adap\u00adsing-remitting-MS. Accessed October 8 2014."},{"key":"key-10.17116\/jnevro20151158225-35-4","doi-asserted-by":"crossref","unstructured":"Weinshenker BG. The natural history of multiple sclerosis: update 1998. Semin Neurol. 1998;18:301-307.","DOI":"10.1055\/s-2008-1040881"},{"key":"key-10.17116\/jnevro20151158225-35-5","doi-asserted-by":"crossref","unstructured":"Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112(1):133-146.","DOI":"10.1093\/brain\/112.1.133"},{"key":"key-10.17116\/jnevro20151158225-35-6","doi-asserted-by":"crossref","unstructured":"Koch M, Kingwell E, Rieckmann P et al. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81:1039-1043.","DOI":"10.1136\/jnnp.2010.208173"},{"key":"key-10.17116\/jnevro20151158225-35-7","unstructured":"Biogen, TYSABRI (natalizumab) Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000603\/WC500044686.pdf. 2014."},{"key":"key-10.17116\/jnevro20151158225-35-8","doi-asserted-by":"crossref","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E et al. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New Engl J Med. 2006;354:899-910.","DOI":"10.1056\/NEJMoa044397"},{"key":"key-10.17116\/jnevro20151158225-35-9","doi-asserted-by":"crossref","unstructured":"Butzkueven H, Kappos L, Pellegrini F et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;85:1190-1197.","DOI":"10.1136\/jnnp-2013-306936"},{"key":"key-10.17116\/jnevro20151158225-35-10","doi-asserted-by":"crossref","unstructured":"Voloshyna N, Havrdov\u00e1 E, Hutchinson M et al. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM. Eur J Neurol. 2015;22:570-577.","DOI":"10.1111\/ene.12618"},{"key":"key-10.17116\/jnevro20151158225-35-11","doi-asserted-by":"crossref","unstructured":"Havrdova E, Galetta S, Hutchinson M et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254-260.","DOI":"10.1016\/S1474-4422(09)70021-3"},{"key":"key-10.17116\/jnevro20151158225-35-12","doi-asserted-by":"crossref","unstructured":"Holm\u00e9n C, Piehl F, Hillert J et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler. 2011;17:708-719.","DOI":"10.1177\/1352458510394701"},{"key":"key-10.17116\/jnevro20151158225-35-13","doi-asserted-by":"crossref","unstructured":"O\u2019Connor P, Goodman A, Kappos L et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology. 2014;83.","DOI":"10.1212\/WNL.0000000000000541"},{"key":"key-10.17116\/jnevro20151158225-35-14","doi-asserted-by":"crossref","unstructured":"Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New Engl J Med. 2006;354:911-923.","DOI":"10.1056\/NEJMoa044396"},{"key":"key-10.17116\/jnevro20151158225-35-15","doi-asserted-by":"crossref","unstructured":"Sangalli F, Moiola L, Bucello S et al. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci. 2011;31(suppl 3):299-302.","DOI":"10.1007\/s10072-010-0344-z"},{"key":"key-10.17116\/jnevro20151158225-35-16","unstructured":"Vukusic S, Passante N, Dufour M et al. TYSEDMUS: five year results. Presented at: 28th Congress of ECTRIMS, Lyon, France, 10\u201413 October 2012."},{"key":"key-10.17116\/jnevro20151158225-35-17","doi-asserted-by":"crossref","unstructured":"Wilken J, Kane RL, Sullivan CL et al. Changes in fatigue and cognition in patients with relapsing forms of multiple sclerosis treated with natalizumab. Int J MS Care. 2013;15:120-129.","DOI":"10.7224\/1537-2073.2012-043"},{"key":"key-10.17116\/jnevro20151158225-35-18","doi-asserted-by":"crossref","unstructured":"Oturai AB, Koch-Henriksen N, Petersen T et al. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol. 2009;16:420-423.","DOI":"10.1111\/j.1468-1331.2008.02517.x"},{"key":"key-10.17116\/jnevro20151158225-35-19","doi-asserted-by":"crossref","unstructured":"Melin A, Outteryck O, Collongues N et al. Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis. J Neurol. 2012;259:1215-1221.","DOI":"10.1007\/s00415-011-6339-8"},{"key":"key-10.17116\/jnevro20151158225-35-20","doi-asserted-by":"crossref","unstructured":"Outteryck O, Ongagna JC, Brochet B et al. A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. Eur J Neurol. 2014;21:40-48.","DOI":"10.1111\/ene.12204"},{"key":"key-10.17116\/jnevro20151158225-35-21","doi-asserted-by":"crossref","unstructured":"Mancardi GL, Tedeschi G, Amato MP et al. Three years of experience: the Italian registry and safety data update. Neurol Sci. 2011;31(suppl 3):295-297.","DOI":"10.1007\/s10072-010-0356-8"},{"key":"key-10.17116\/jnevro20151158225-35-22","doi-asserted-by":"crossref","unstructured":"Totaro R, Lugaresi A, Bellantonio P et al. Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. Int J Immunopathol Pharmacol. 2013;27:147-154.","DOI":"10.1177\/039463201402700201"},{"key":"key-10.17116\/jnevro20151158225-35-23","doi-asserted-by":"crossref","unstructured":"Outteryck O, Ongagna JC, Z\u00e9phir H et al. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol. 2010;257:207-211.","DOI":"10.1007\/s00415-009-5294-0"},{"key":"key-10.17116\/jnevro20151158225-35-24","doi-asserted-by":"crossref","unstructured":"Putzki N, Yaldizli O, M\u00e4urer M et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol. 2010;17:31-37.","DOI":"10.1111\/j.1468-1331.2009.02728.x"},{"key":"key-10.17116\/jnevro20151158225-35-25","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez O, Oreja-Guevara C, Arroyo R et al. Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. J Neurol. 2012;259:1814-1823.","DOI":"10.1007\/s00415-012-6414-9"},{"key":"key-10.17116\/jnevro20151158225-35-26","doi-asserted-by":"crossref","unstructured":"Krysko KM, O\u2019Connor PW. The toronto observational study of natalizumab in multiple sclerosis. Can J Neurol Sci. 2011;38:422-428.","DOI":"10.1017\/S0317167100011811"},{"key":"key-10.17116\/jnevro20151158225-35-27","doi-asserted-by":"crossref","unstructured":"Alroughani R, Al Hashel J, Thussu A et al. Use of natalizumab in patients with active relapsing-remitting multiple sclerosis in Kuwait. Med Princ Pract. 2013;22:495-499.","DOI":"10.1159\/000351568"},{"key":"key-10.17116\/jnevro20151158225-35-28","doi-asserted-by":"crossref","unstructured":"Belachew S, Phan-Ba R, Bartholom\u00e9 E et al. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18:240-245.","DOI":"10.1111\/j.1468-1331.2010.03112.x"},{"key":"key-10.17116\/jnevro20151158225-35-29","doi-asserted-by":"crossref","unstructured":"Lanzillo R, Bonavita S, Quarantelli M et al. Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. Neurol Sci. 2013;34:521-528.","DOI":"10.1007\/s10072-012-1088-8"},{"key":"key-10.17116\/jnevro20151158225-35-30","doi-asserted-by":"crossref","unstructured":"Putzki N, Yaldizli O, Buhler R et al. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol. 2010;63:101-106.","DOI":"10.1159\/000276400"},{"key":"key-10.17116\/jnevro20151158225-35-31","doi-asserted-by":"crossref","unstructured":"Marrosu MG, Lorefice L, Frau J et al. The cohort of the multiple sclerosis center of Cagliari. Neurol Sci. 2011;31(suppl 3):309-312.","DOI":"10.1007\/s10072-010-0470-7"},{"key":"key-10.17116\/jnevro20151158225-35-32","doi-asserted-by":"crossref","unstructured":"Prosperini L, Borriello G, Fubelli F et al. Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome. Neurol Sci. 2011;31(suppl 3):303-307.","DOI":"10.1007\/s10072-010-0348-8"},{"key":"key-10.17116\/jnevro20151158225-35-33","doi-asserted-by":"crossref","unstructured":"Kallweit U, Jelcic I, Braun N et al. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort. Clin Neuropharmacol. 2012;35:77-80.","DOI":"10.1097\/WNF.0b013e31824644e6"},{"key":"key-10.17116\/jnevro20151158225-35-34","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez O, Alvarenga MP, Guerrero M et al. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study. Mult Scler. 2011;17:192-197.","DOI":"10.1177\/1352458510385507"},{"key":"key-10.17116\/jnevro20151158225-35-35","doi-asserted-by":"crossref","unstructured":"Prosperini L, Giann\u00ec C, Barletta V et al. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. J Neurol Sci. 2012;323:104-112.","DOI":"10.1016\/j.jns.2012.08.027"},{"key":"key-10.17116\/jnevro20151158225-35-36","doi-asserted-by":"crossref","unstructured":"Fernandez-Megia MJ, Casanova B, Magraner MJ et al. Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis. Farm Hosp. 2011;35:75-79.","DOI":"10.1016\/S2173-5085(11)70012-0"},{"key":"key-10.17116\/jnevro20151158225-35-37","doi-asserted-by":"crossref","unstructured":"Stephenson JJ, Kern DM, Agarwal SS et al. Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study. Health QualLife Outcomes. 2012;10:155.","DOI":"10.1186\/1477-7525-10-155"},{"key":"key-10.17116\/jnevro20151158225-35-38","doi-asserted-by":"crossref","unstructured":"Kamat SA, Rajagopalan K, Stephenson JJ et al. Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey. Patient. 2009;2:105-112.","DOI":"10.2165\/01312067-200902020-00006"},{"key":"key-10.17116\/jnevro20151158225-35-39","doi-asserted-by":"crossref","unstructured":"Rudick RA, Miller D, Hass S et al. Health-related quality of life in multiple sclerosis: Effects of natalizumab. Ann Neurol. 2007;62:335-346.","DOI":"10.1002\/ana.21163"},{"key":"key-10.17116\/jnevro20151158225-35-40","doi-asserted-by":"crossref","unstructured":"Phillips JT, Giovannoni G, Lublin FD et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler. 2011;17:970-979.","DOI":"10.1177\/1352458511399611"},{"key":"key-10.17116\/jnevro20151158225-35-41","doi-asserted-by":"crossref","unstructured":"Weber T. Progressive Multifocal Leukoencephalopathy. Neurologic Clinics. 2008;26:833-854.","DOI":"10.1016\/j.ncl.2008.03.007"},{"key":"key-10.17116\/jnevro20151158225-35-42","doi-asserted-by":"crossref","unstructured":"Kappos L, Bates D, Hartung HP et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurology. 2007;6:431-441.","DOI":"10.1016\/S1474-4422(07)70078-9"},{"key":"key-10.17116\/jnevro20151158225-35-43","doi-asserted-by":"crossref","unstructured":"Bloomgren G, Richman S, Hotermans C et al. Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. New Engl J Med. 2012;366:1870-1880.","DOI":"10.1056\/NEJMoa1107829"},{"key":"key-10.17116\/jnevro20151158225-35-44","doi-asserted-by":"crossref","unstructured":"Khalili K, White MK, Lublin F et al. Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology. 2007;68:985-990.","DOI":"10.1212\/01.wnl.0000257832.38943.2b"},{"key":"key-10.17116\/jnevro20151158225-35-45","doi-asserted-by":"crossref","unstructured":"Kappos L, Bates D, Edan G et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. LancetNeurol. 2011;10:745-758.","DOI":"10.1016\/S1474-4422(11)70149-1"},{"key":"key-10.17116\/jnevro20151158225-35-46","doi-asserted-by":"crossref","unstructured":"Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis. 2002;186(suppl):180-186.","DOI":"10.1086\/344280"},{"key":"key-10.17116\/jnevro20151158225-35-47","doi-asserted-by":"crossref","unstructured":"Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292-302.","DOI":"10.1002\/ana.22366"},{"key":"key-10.17116\/jnevro20151158225-35-48","doi-asserted-by":"crossref","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.","DOI":"10.1212\/WNL.33.11.1444"},{"key":"key-10.17116\/jnevro20151158225-35-49","unstructured":"Ware J. SF-36 Health Survey Update."},{"key":"key-10.17116\/jnevro20151158225-35-50","doi-asserted-by":"crossref","unstructured":"Ware JEJr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.","DOI":"10.1097\/00005650-199206000-00002"},{"key":"key-10.17116\/jnevro20151158225-35-51","doi-asserted-by":"crossref","unstructured":"Turner-Bowker DM, Saris-Baglama RN, and Derosa MA. Single-item electronic administration of the SF-36 v2 Health Survey. Qual Life Res. 2013;22:485-490.","DOI":"10.1007\/s11136-012-0169-8"},{"key":"key-10.17116\/jnevro20151158225-35-52","doi-asserted-by":"crossref","unstructured":"Hobart J, Lamping D, Fitzpatrick R et al. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001;124:962-973.","DOI":"10.1093\/brain\/124.5.962"},{"key":"key-10.17116\/jnevro20151158225-35-53","doi-asserted-by":"crossref","unstructured":"Trojano M, Lucchese G, Graziano G et al. Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS One. 2012;7:48078.","DOI":"10.1371\/journal.pone.0048078"},{"key":"key-10.17116\/jnevro20151158225-35-54","doi-asserted-by":"crossref","unstructured":"Bove R, Chitnis T. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler. 2014;20:520-526.","DOI":"10.1177\/1352458513519181"},{"key":"key-10.17116\/jnevro20151158225-35-55","doi-asserted-by":"crossref","unstructured":"Bove R, Chitnis T. Sexual disparities in the incidence and course of MS. Clin Immunol. 2013;149:201-210.","DOI":"10.1016\/j.clim.2013.03.005"},{"key":"key-10.17116\/jnevro20151158225-35-56","doi-asserted-by":"crossref","unstructured":"Dahdaleh D, Altmann DM, Malik O et al. Breathlessness, night sweats, and weight loss on natalizumab. The Lancet. 2012;380:726-727.","DOI":"10.1016\/S0140-6736(12)61401-9"},{"key":"key-10.17116\/jnevro20151158225-35-57","doi-asserted-by":"crossref","unstructured":"Adoni T, Anacleto A, Jesus MD et al. How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis? Expert Rev Neurother. 2014;14:0.","DOI":"10.1586\/14737175.2014.962517"},{"key":"key-10.17116\/jnevro20151158225-35-58","doi-asserted-by":"crossref","unstructured":"Mulero P, Caminero AB, Neri Crespo MJ et al. Latent tuberculosis seems not to reactivate in multiple sclerosis patients on natalizumab. Journal ofNeuroimmunology. 2012;243:103-105.","DOI":"10.1016\/j.jneuroim.2011.12.009"},{"key":"key-10.17116\/jnevro20151158225-35-59","unstructured":"The National Academies Collection, The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective: Summary of a Joint Workshop. 2011: Washington."},{"key":"key-10.17116\/jnevro20151158225-35-60","unstructured":"Zellweger JP. Current issues in the management of tuberculosis in Europe. Panminerva Med. 2013;55:145-155."},{"key":"key-10.17116\/jnevro20151158225-35-61","doi-asserted-by":"crossref","unstructured":"Plavina T, Subramanyam M, Bloomgren G et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76:802-812.","DOI":"10.1002\/ana.24286"},{"key":"key-10.17116\/jnevro20151158225-35-62","doi-asserted-by":"crossref","unstructured":"Olsson T, Achiron A, Alfredsson L et al. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler. 2013;19:1533-1538.","DOI":"10.1177\/1352458513477925"},{"key":"key-10.17116\/jnevro20151158225-35-63","doi-asserted-by":"crossref","unstructured":"Havrdova E, Galetta S, Stefoski D et al. Freedom from disease activity in multiple sclerosis. Neurology. 2010;74.","DOI":"10.1212\/WNL.0b013e3181dbb51c"},{"key":"key-10.17116\/jnevro20151158225-35-64","doi-asserted-by":"crossref","unstructured":"Stangel M, Penner IK, Kallmann BA et al. Towards the implementation of \u2018no evidence of disease activity\u2019 in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord. 2015;8:3-13.","DOI":"10.1177\/1756285614560733"}],"container-title":["Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T14:00:06Z","timestamp":1567778406000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova-2\/2015\/8\/downloads\/ru\/271997-72982015085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":64,"journal-issue":{"issue":"8. Vyp. 2","published-print":{"date-parts":[[2015]]}},"alternative-id":["jnevro20151158225-35"],"URL":"https:\/\/doi.org\/10.17116\/jnevro20151158225-35","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}